The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Synaptic Targeting by Alzheimer's-Related Amyloid β Oligomers
Open accessAbstract
The cognitive hallmark of early Alzheimer's disease (AD) is an extraordinary inability to form new memories. For many years, this dementia was attributed to nerve-cell death induced by deposits of fibrillar amyloid beta (Abeta). A newer hypothesis has emerged, however, in which early memory loss is considered a synapse failure caused by soluble Abeta oligomers. Such oligomers rapidly block long-term potentiation, a classic experimental paradigm for synaptic plasticity, and they are strikingly elevated in AD brain tissue and transgenic-mouse AD models. The current work characterizes the manner in which Abeta oligomers attack neurons. Antibodies raised against synthetic oligomers applied to AD brain sections were found to give diffuse stain around neuronal cell bodies, suggestive of a dendritic pattern, whereas soluble brain extracts showed robust AD-dependent reactivity in dot immunoblots. Antigens in unfractionated AD extracts attached with specificity to cultured rat hippocampal neurons, binding within dendritic arbors at discrete puncta. Crude fractionation showed ligand size to be between 10 and 100 kDa. Synthetic Abeta oligomers of the same size gave identical punctate binding, which was highly selective for particular neurons. Image analysis by confocal double-label immunofluorescence established that >90% of the punctate oligomer binding sites colocalized with the synaptic marker PSD-95 (postsynaptic density protein 95). Synaptic binding was accompanied by ectopic induction of Arc, a synaptic immediate-early gene, the overexpression of which has been linked to dysfunctional learning. Results suggest the hypothesis that targeting and functional disruption of particular synapses by Abeta oligomers may provide a molecular basis for the specific loss of memory function in early AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among these various forms, soluble Aβ aggregates are more toxic than monomers or insoluble fibrils; thus, reducing these soluble Aβ aggregates could represent a practical treatment approach in the early stages of AD [10,11,12].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite ongoing debate, Aβ accumulation, whether in the form of insoluble plaques, or smaller soluble oligomers does appear to be a primary driver of the disease process, particularly linked to synapse dysfunction [3].”
From Heterozygous expression of the Alzheimer’s disease-protective PLCγ2 P522R variant enhances Aβ clearance while preserving synapses (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Conversely, overexpression of APP and its proteolytic product, Aβ, have been implicated in the synaptic losses seen early in the development of AD [27].”
From FMRP Mediates mGluR5-Dependent Translation of Amyloid Precursor Protein (2007) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other suggested Aβ binding partners at synapses include the α7-nicotinic receptor [49], Ephrin A4 [73], PSD95 [35, 50, 52] and LilrB2 [32].”
From Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer’s disease (2024) · cites this paper as [35]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Among these various forms, soluble Aβ aggregates are more toxic than monomers or insoluble fibrils; thus, reducing these soluble Aβ aggregates could represent a practical treatment approach in the early stages of AD [10,11,12].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [12]
The cited source says what the claim attributes to it.
In the citing paper
“As previously discussed, amyloid-β oligomers bind to synapses [144] and interfere with the normal process of neurotransmission, long-term potentiation, and thereby memory formation [145].”
From Sigma-2 Receptors—From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases (2023) · cites this paper as [144]
In the citing paper
“Immunohistochemistry confirms that oligomers associate with neurons, accumulating very early in disease progression (Lacor et al., 2004), in loci distinct from amyloid deposits (Kayed et al., 2003).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lacor et al., 2004
In the citing paper
“as have the related predictions that oligomers cause dysfunctional trafficking of ionotropic glutamate receptors and metabotropic glutamate receptors (Gong et al., 2003; Lacor et al., 2004).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lacor et al., 2004
In the citing paper
“The possible source of extracellular oligomers and how they interact with neurons in human brain are suggested by their peri-somatic localization, observed in early-stage disease (Figure 1, left; (Lacor et al., 2004)).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lacor et al., 2004
In the citing paper
“The same binding specificity and punctate pattern is observed for synthetic oligomers, particularly those greater than 50 kDa (Lacor et al., 2004).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lacor et al., 2004
In the citing paper
“Oligomers show > 90% co-localization with the post-synaptic marker PSD-95 (Lacor et al., 2004).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lacor et al., 2004
In the citing paper
“This prediction was first confirmed for NMDA-Rs (Lacor et al., 2004; Lacor et al., 2007; Snyder et al., 2005).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lacor et al., 2004
In the citing paper
“One rapid consequence is an aberrant expression of Arc (Activity-Regulated Cytoskeletal associated protein; (Lacor et al., 2004)).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lacor et al., 2004
In the citing paper
“Because Arc is an actin binding protein, its aberrant expression was predicted to disrupt receptor trafficking (Lacor et al., 2004), which could consequently disrupt plasticity (Gong et al., 2003).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lacor et al., 2004
In the citing paper
“Coupled with the potential of dendrites for activity-stimulated exocytosis (Kennedy et al., 2010), such a phenomenon could account for the “perineuronal deposits” of oligomers seen in Figure 1 (Lacor et al., 2004).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lacor et al., 2004
In the citing paper
“All of these processes are affected by Aβ oligomers in vitro, using primary neuronal cultures (12, 15, 36, 37).”
From Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein (2010) · cites this paper as [37]
In the citing paper
“Furthermore, extracellular Aβ1-42 oligomers preferentially target synapses when added to neurons [43, 91].”
From Intraneuronal β-amyloid accumulation and synapse pathology in Alzheimer’s disease (2010) · cites this paper as [91]
In the citing paper
“Other binding partners that have been suggested to bind Aβ include the α7-nicotinic receptor [49], Ephrin A4 (EphA4) [73], PSD95 [35, 50, 52] or LilrB2 [32].”
From Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer’s disease (2024) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Self-citationPathways towards and Away from Alzheimer’s Disease
Mattson, M. P. (2004) · Nature · doi:10.1038/nature02621 · Cited by 3,052
Mucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., & McConlogue, L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04050.2000 · Cited by 1,856
Research works printed but not linked: 2
- Klein WL (2004) Cytotoxic intermediates in the fibrillation pathway: Aβ oligomers in Alzheimer's disease as a case study. In: Protein misfolding, aggregation and conformational diseases (Uversky V, ed). New York: Kluwer Academic/Plenum, in press.
- 2002, Nat Rev Neurosci, 3, 824
Cited by
Sorted by citations
Items 801–900 of 949
Canonica, T., Kidd, E. J., Gibbins, D., Lana‐Elola, E., Fisher, E., Tybulewicz, V. L. J., & Good, M. A. (2024) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2024.1428146 · Cited by 4
Thitilertdecha, P., & Brimson, J. M. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230994 · Cited by 3
Vugmeyster, L., Au, D. F., Frazier, B., Qiang, W., & Ostrovsky, D. (2024) · Physical Chemistry Chemical Physics · doi:10.1039/d3cp04824a · Cited by 3
Hippocampal Neural Stem Cell Exosomes Promote Brain Resilience against the Impact of Tau Oligomers
Krishnan, B., Marcatti, M., Fracassi, A., Zhang, W.-R., Guptarak, J., Johnson, K. M., Grant, A. C., Kayed, R., Taglialatela, G., & Micci, M. (2025) · Journal of Neuroscience · doi:10.1523/jneurosci.1664-24.2025 · Cited by 3
Gomi, F., Uchida, Y., & Endo, S. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.06.035 · Cited by 3
Parodí, J. (2018) · Current Chemical Biology · doi:10.2174/2212796812666180710125905 · Cited by 3
Glycodendrimers as Potential Multitalented Therapeutics in Alzheimer’s Disease
Klementieva, O. L. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.88974 · Cited by 3
Group I metabotropic glutamate receptors (mGluR1/5) and neurodegenerative diseases
Solntseva, E. I., Rogozin, P. D., & Skrebitsky, V. G. (2019) · Annals of Clinical and Experimental Neurology · doi:10.25692/acen.2019.4.8 · Cited by 3
Animal Models for Brain Research
Dam, D. V., & Deyn, P. P. D. (2020) · Springer eBooks · doi:10.1007/978-3-030-53176-8_1 · Cited by 3
Shin, K.-S., Kim, M. J., Lee, S. H., & Kang, J. Y. (2015) · IEEE International Conference on Micro Electro Mechanical Systems (MEMS) · doi:10.1109/memsys.2015.7051028 · Cited by 3
Does the electrical activity of neurons contribute to the pathogenesis of Alzheimer’s Disease?
Concepción, G. P., & PADLAN, E. A. (2009) · Medical Hypotheses · doi:10.1016/j.mehy.2009.08.023 · Cited by 3
Neurodegenerative Diseases as Protein Folding Disorders
Baker, J. D., Webster, J. M., Shelton, L. B., Koren, J., Uversky, V. N., Blair, L. J., & Dickey, C. A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811304-2.00009-2 · Cited by 3
Neurochemical Aspects of Neurodegenerative Diseases
Farooqui, A. A. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6652-0_8 · Cited by 3
The amyloid cascade: The old and the new
Marcello, E. E., Epis, R., Gardoni, F., & Luca, M. D. (2008) · The journal of nutrition health & aging · doi:10.1007/bf02982588 · Cited by 3
Neurochemical Aspects of Alzheimer Disease
Farooqui, A. A. (2016) · Springer eBooks · doi:10.1007/978-3-319-15889-1_1 · Cited by 2
Almeida, D. S., dos Santos, R. S., Anjos, M. J., Ferreira, S. T., de Souza, A. S., & Lopes, R. T. (2017) · X-Ray Spectrometry · doi:10.1002/xrs.2753 · Cited by 2
Obulesu, M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816412-9.00001-x · Cited by 3
Arce, F. T., Jang, H., Connelly, L. S., Ramachandran, S., Kagan, B. L., Nussinov, R., & Lal, R. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394431-3.00036-5 · Cited by 3
Liu, J., Gao, X., & Wu, Y. (2008) · Neuroembryology and Aging · doi:10.1159/000193851 · Cited by 2
Bu, R. L., Clark, J. R., DiChiara, T., Sligar, S. G., & Klein, W. L. (2018) · Neuromethods · doi:10.1007/978-1-4939-8739-9_13 · Cited by 2
Self-citationSiqueira, L. D., Celes, A. P. M., dos Santos, H., & Ferreira, S. T. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210139 · Cited by 2
Duyckaerts, C. J. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781107588660.007 · Cited by 2
Vasconcelos, B., Bird, M., Stancu, I., Terwel, D., & Dewachter, I. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-805120-7.00006-3 · Cited by 2
Tam, J. H. K., & Pasternak, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801942-9.00004-5 · Cited by 2
Stefani, M. (2010) · Wiley eBooks · doi:10.1002/9780470572702.ch5 · Cited by 2
An Individualized Approach to Treatment for Alzheimer’s Disease, Pick’s Disease, and Other Dementias
Lippa, C. F. (2006) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317506292372 · Cited by 2
Marsh, S. (2015) · Research Explorer (The University of Manchester) · Cited by 2
Design of non-aggregating variants of Aβ peptide
Caine, J. M., Churches, Q. I., Waddington, L. J., Nigro, J., Breheney, K., Masters, C. L., Nuttall, S. D., & Streltsov, V. A. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.09.102 · Cited by 1
Nagahama, T., Nakajima, H., Wakuta, M., Kasahara, Y., Narita, K., & Nagahama, S. (2023) · Neuroscience Research · doi:10.1016/j.neures.2023.06.004 · Cited by 1
Dietz, L. T., Põld, K., Györffy, B. A., Zharkovsky, A., Sørensen, J. B., Pankratova, S., & Dmytriyeva, O. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04475-z · Cited by 1
Donoso-González, O., Jara-Guajardo, P., Cabrera, P., Hengsbach, R., Noyong, M., Aldunate, R., Sierpe, R., Araya, E., Célis, F., Melo, F., et al. (2024) · Materials Today Chemistry · doi:10.1016/j.mtchem.2024.102482 · Cited by 1
Xie, Y., Meng, X. W., Li, T., Zhang, H., Zheng, Y., Kim, S.-Y., Zhang, C., Yu, X., & Wang, H. (2025) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70064 · Cited by 1
Dai, Y.-T., Chen, Q., Ma, Y.-D., Liu, H., Zheng, H., Zhu, Y.-Y., Gao, L., Zhao, Q., Bai, J.-L., Fan, Y.-C., et al. (2026) · Neuropharmacology · doi:10.1016/j.neuropharm.2026.110887 · Cited by 1
Ojeda-Juárez, D., Funk, G., McClatchy, D. B., Richards, E., Rajic, A. J., Soldau, K., Geschwind, M. D., Chen, X., Yates, J. R., Gonias, S. L., et al. (2026) · Stem Cell Reports · doi:10.1016/j.stemcr.2026.102924 · Cited by 1
Arriagada, J., Ardiles, Á. O., Mery, E., Garay, C., Conejera, F., Herrera, E. A., Paula-Lima, A. C., & Muñoz, P. (2026) · Neuropharmacology · doi:10.1016/j.neuropharm.2026.111116 · Cited by 1
Conformation-Dependent Antibodies as Tools for Characterization of Amyloid Protein Aggregates
Wu, J., & Breydo, L. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394431-3.00008-0 · Cited by 1
Biological Targeting and Activity of Pre-fibrillar Aβ Assemblies
Wilcox, K. C., Pitt, J. E., Sebollela, A. S., Martirosova, H., Lacor, P. N., & Klein, W. L. (2011) · Springer eBooks · doi:10.1007/978-94-007-2774-8_4 · Cited by 1
Self-citationNanomaterials for Diagnostic Imaging of the Brain
Qin, E. C., & Kong, H. (2015) · Biosystems & biorobotics · doi:10.1007/978-3-319-21813-7_4 · Cited by 1
The Role of Rodent Models in the Drug Discovery Pipeline for Dementia
Dam, D. V., & Deyn, P. P. D. (2010) · Neuromethods · doi:10.1007/978-1-60761-898-0_3 · Cited by 1
Stephens, G. S., You, J. C., Fu, C.-H., & Chin, J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809324-5.21126-7 · Cited by 1
Vigour of CRISPR/Cas9 Gene Editing in Alzheimer’s Disease
Jes, P. (2018) · Journal of Neuroscience and Neurological Disorders · doi:10.29328/journal.jnnd.1001014 · Cited by 1
Polyphenols attenuate mitochondrial dysfunction induced by amyloid peptides
Alberdi, E. M., Ruiz, A., Sánchez‐Gómez, M. V., Capetillo‐Zarate, E., & Matute, C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821562-3.00003-4 · Cited by 1
Traits and Trammels of Tau Tracer Imaging
Villemagne, V. L., Lopresti, B. J., Doré, V., Minhas, D. S., Gogola, A., Nadkarni, N. K., Mason, N. S., Bourgeat, P., López, O. L., Ikonomović, M. D., et al. (2023) · Springer eBooks · doi:10.1007/978-3-031-35098-6_6 · Cited by 1
Place cell physiology in a transgenic mouse model of Alzheimer's disease
Yi, M. (2009) · Cited by 1
Loss of Synaptophysin Immunoexpression in Primary Progressive Aphasia
Lippa, C. F., & Rosso, A. L. (2012) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317512446187 · Cited by 1
Molecular Mechanism Underlying Aβ Immunotherapy: Implications for the Toxic Action of Aβ Oligomers
Matsubara, E. (2013) · Journal of Gerontology & Geriatric Research · doi:10.4172/2167-7182.s2-001 · Cited by 1
Diet, Abeta Oligomers and Defective Insulin and Neurotrophic Factor Signaling in Alzheimer’s Disease
Cole, G. M., Ma, Q., Yang, F., Deshpande, A. M., Ubeda, O. J., & Frautschy, S. A. (2010) · Research and perspectives in Alzheimer's disease · doi:10.1007/978-3-642-04300-0_11 · Cited by 1
Ginkgo biloba Extract in Prevention of Age-Associated Diseases in Elderly Population
Luo, Y., & Cao, Z. (2009) · Elsevier eBooks · doi:10.1016/b978-0-12-374228-5.00006-8 · Cited by 1
Physiologic and Neurotoxic Properties of Aβ Peptides
Gregory, G. C., Shepherd, C. E., & Halliday, G. M. (2006) · Springer eBooks · doi:10.1007/978-1-84628-440-3_11 · Cited by 1
Animal Models for Brain Research
Dam, D. V., & Deyn, P. P. D. (2014) · Springer eBooks · doi:10.1007/978-3-642-42014-6_1 · Cited by 1
Development of Therapeutic Strategies for the Transthyretin Amyloidoses
Fearns, C., Connelly, S., Powers, E. T., & Kelly, J. W. (2013) · Wiley eBooks · doi:10.1002/9783527654185.ch17 · Cited by 1
Interaction of Alzheimer Amyloid Peptide with Cell Surfaces and Artificial Membranes
Bateman, D. A., & Chakrabartty, A. (2011) · Wiley eBooks · doi:10.1002/9783527634323.ch11 · Cited by 1
Entrada de calcio inducida por los oligómeros del péptido amiloide en la Enfermedad de Alzheimer
Ortega, E. C. (2013) · UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid) · doi:10.35376/10324/3786 · Cited by 1
Maliszewska‐Cyna, E. (2016) · TSpace (University of Toronto) · Cited by 1
Arc: a therapeutic hub for Alzheimer’s diseasePreprint
VanDongen, A. M. J. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.16.632170 · Cited by 1
NAD+ hydrolase Sarm1 is a key driver of synapse degeneration and memory loss in Alzheimer’s disease
Fan, F., Joshi, P., Liu, X., Kotturu, S. K., Abiola, M., Liu, Q., & Lou, X. (2025) · doi:10.64898/2025.12.21.695860
Signaling Mechanisms that Mediate Aβ Induced Neuronal Dysfunction
Cotman, C. W., & Busciglio, J. A. (2007) · Springer eBooks · doi:10.1007/978-0-387-35135-3_8
Disruptive effects of Abeta oligomers to the radial -arm maze performance of rats
Morgan-Paisley, K. (2008)
Chapter 1 Amyloid and Amyloid-Like Protein Aggregates in Neurodegenerative Disease
Golde, T. E. (2007) · Blue books of neurology · doi:10.1016/s1877-184x(09)70052-8
Wang, L., & Campioni, S. (2011) · InTech eBooks · doi:10.5772/20922
Approaches to Amyloid Therapies for the Treatment of Alzheimer's Disease
Robichaud, A. J., Kim, J., & Jacobsen, J. S. (2010) · Wiley eBooks · doi:10.1002/0471266949.bmc249
Vukic, V. (2008) · uO Research (University of Ottawa) · doi:10.20381/ruor-12230
Endosomes élargis et cholestérol : De la trisomie 21 à la maladie d'Alzheimer
Cossec, J. (2009) · OpenGrey (Institut de l'Information Scientifique et Technique)
Regenerating the brain: Stem cell differentiation and cholinergic dysfunction in Alzheimer disease
Malmsten, L. (2014) · Figshare
Murtishaw, A. S. (2020) · Digital Scholarship - UNLV (University of Nevada Reno) · doi:10.34917/6456429
Single particle tracking of amyloid oligomers on the plasma membrane of living cells
Calamai, M., & Pavone, F. S. (2011) · International Workshop on Biophotonics · doi:10.1109/iwbp.2011.5954833
Acide docosahexaénoïque et maladie d’Alzheimer : des raisons d’espérer ?
Florent‐Béchard, S., Youssef, I., Malaplate, C., Koziel, V., Leininger‐Muller, B., Kriem, B., Olivier, J. L., Oster, T., & Pillot, T. (2007) · Oléagineux Corps gras Lipides · doi:10.1051/ocl.2007.0101 · Cited by 1
Alzheimer‘s disease therapy: focus on synapses
Gouras, G. K. (2007) · Future Neurology · doi:10.2217/14796708.2.5.469
SPECIFIC AMYLOID-BETA OLIGOMERS IN HUMAN CEREBROSPINAL FLUID
Handoko, M. (2012) · University of Minnesota Digital Conservancy (University of Minnesota)
da Silva, T. (2012) · Americanae (AECID Library)
Kilimann, I., Grothe, M. J., Thyrian, J. R., & Teipel, S. J. (2016) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-016-1588-9
Structural biology of bacterial functional amyloid formation
Hawthorne, W. J. (2015) · Spiral (Imperial College London) · doi:10.25560/30780
Busciglio, J. A., & Deshpande, A. M. (2008) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195369007.003.0010
Intraneuronal Amyloid and Cognitive Impairment
D’Andrea, M. R. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-804256-4.00006-1
Rommy von Bernhardi, M. (2005)
Substanz(en) Firma/Institution Studienname Phase/Status Teilnehmer (Anzahl) Ergebnisse Referenzen
Janssen, B., Lilly, S. E., & Uni, W. (2016)
Identifying the mechanism of Aβ42 inhibition of PDGF-BB signalling
Saffi, G. T. (2014) · UWSpace (University of Waterloo)
Neurochemical Aspects of β-Amyloid Cascade Hypothesis for Alzheimer’s Disease
Farooqui, A. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809937-7.00001-x · Cited by 1
Perspective, Summary, and Directions for Future Research on Alzheimer’s Disease
Farooqui, A. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809937-7.00010-0
Lundgren, J. L. (2018) · Figshare
Terapia celular y génica con timulina E IGF-1 en modelos animales de neuroinflamación
Villar, M. F. Z. (2018) · El Servicio de Difusión de la Creación Intelectual (National University of La Plata) · doi:10.35537/10915/71572
The Roles of Diffusion and Bulk Flow in Neural Function and Alzheimer's Disease
Dauberman, W. N. (2017)
Structure and dynamics of the MAGUK core of PSD-95
Zhang, J. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/wyec-7388
Dhénain, M. (2015) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)30893-3
Cognitive function in mice with segmental trisomy of human chromosome 21 Down Syndrome genes
Canonica, T. (2019) · ORCA Online Research @Cardiff (Cardiff University)
Fruit bromelain derived peptides destabilize growth of amyloidal fibrilsPreprint
Das, S., Dutta, S. M., Paidi, R. K., Biswas, S. C., Halder, U. C., & Bhattacharyya, D. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.20.051193
Effects of anle138b treatment on amyloid-β neurotoxicity
Thomas, C. (2020) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-8233
Clarke, J. R., Silva, N. M. L. E., Figueiredo, C. P., Frozza, R. L., Ledo, J. H., Beckman, D., Katashima, C. K., Razolli, D. S., Carvalho, B. M., Frazão, R., et al. (2015) · Americanae (AECID Library) · doi:10.15252/emmm.201404183/abstract
Self-citationRole of Aβ Degrading Enzymes in Synaptic Plasticity and Neurogenesis in Alzheimer’s Disease
Crews, L. A., Spencer, B. J., & Masliah, E. (2009) · Springer eBooks · doi:10.1007/978-0-387-87995-6_1
Mechanisms involved in amyloid induced cytotoxicity
Östman, J. (2005) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Perspective Chapter: Alzheimer - A Complex Genetic Background
Calabrò, M., & Crisafulli, C. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.101455
Zampar, S. (2021) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-9004
Aβ-Induced Alterations in Membrane Lipids Occur before Synaptic Loss Appears
Bulck, M. V., Brandt, N., Claus, R. A., Gräler, M. H., & Bräuer, A. U. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042300
Catalano, S. M. (2022) · Cambridge University Press eBooks · doi:10.1017/9781108975759.047
Metadata
- Authors
- Lacor, P. N., Buniel, M. C., Chang, L., Fernandez, S. J., Gong, Y., Viola, K. L., Lambert, M. P., Velasco, P. T., Bigio, E. H., Finch, C. E., Krafft, G. A., & Klein, W. L.
- Affiliations
- Northwestern University (US)
- University of Southern California (US)
- Acumen Pharmaceuticals (United States) (US)
- Corresponding author
- Klein, William L.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2004-11-10
- Volume
- 24
- Issue
- 45
- Pages
- 10191-10200
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- PMC
- PMC6730194
- OpenAlex
- W2162807572
- Cited by
- 954
- References
- 64
- Citations by year
- 2026: 14 · 2025: 18 · 2024: 24 · 2023: 41 · 2022: 35 · 2021: 28 · 2020: 26 · 2019: 32 · 2018: 41 · 2017: 50 · 2016: 51 · 2015: 50 · 2014: 54 · 2013: 65 · 2012: 59
- FWCI
- 25.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Illinois Department of Public Health
- Northwestern University
- National Institutes of Health (AG11385)
- National Institute on Aging (R01 AG11385, P30AG13854, R01AG022547, R01-AG22547, R01AG011385, R03AG022237, R01-AG18877, P30AG013854, R01AG018877)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta oligomers, synaptic targeting, long-term potentiation, synaptic plasticity, PSD-95, Arc, hippocampal neurons, memory loss, early Alzheimer's disease
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Animals, Binding Sites, Cerebral Cortex, Cerebrospinal Fluid Proteins, Chromatography, High Pressure Liquid, Cytoskeletal Proteins, Female, Hippocampus, Humans, Male, Nerve Tissue Proteins, Neurons, Peptide Fragments, Protein Binding, Synapses, Tissue Extracts, Amyloid beta-Peptides, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
